REG - Allergy Therapeutics - Authority for allotment of New Shares

Allergy TherapeuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251212:nRSL2924La&default-theme=true

RNS Number : 2924L  Allergy Therapeutics PLC  12 December 2025

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Authority for allotment of up to 610,000,000 New Shares and disapplication of
pre-emption rights to facilitate a Potential Equity Raise

 

Notice of General Meeting to be held on 29 December 2025

 

 

12 December 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, announces
that the Board is considering potentially undertaking an equity raise which
would be structured by issuing New Shares to new investors and/or existing
shareholders in the Company for cash consideration in one or more private
placements on a non-pre-emptive basis (the "Potential Equity Raise").

 

The Potential Equity Raise would be carried out ahead of the potential dual
listing of the Company's shares on the Hong Kong Stock Exchange, which was
announced on 6 November 2025 and which is expected to occur in the first half
of 2026 (the "Hong Kong Listing").

 

In order to facilitate the Potential Equity Raise and to ensure that it could
be swiftly concluded if it progresses, the Board is seeking specific
shareholder approval at a general meeting (the "General Meeting") for the
allotment and issue of up to 610,000,000 ordinary shares of £0.001 each ("New
Shares") (which is approximately 10% of the Company's current issued share
capital) in connection with the Potential Equity Raise, on terms that the
Board may determine.

 

In order for the Directors to issue New Shares free of statutory pre-emption
rights, such statutory pre-emption rights must be dis-applied. Accordingly,
the Board wishes to seek separate authorities to dis-apply pre-emption rights
in respect of the allotment of the New Shares pursuant to the Potential Equity
Raise.

 

The General Meeting will be held at the offices of Cooley (UK) LLP, 22
Bishopsgate, London EC2N 4BQ, United Kingdom at 11:00 a.m. (UK time) on 29
December 2025.

 

At this time, there is no certainty that the Potential Equity Raise will
proceed and at this point no investors have entered into any agreements to
subscribe for New Shares and the amounts and price of any Potential Equity
Raise have not been agreed. To the extent that any money is raised from the
Potential Equity Raise, it would be applied towards the Company's stated
strategy of developing treatments for grass and peanut allergy patients, and
general corporate purposes, including the Company's working capital needs
prior to the Hong Kong Listing.

 

If the authorities sought at the General Meeting in connection with the
Potential Equity Raise are approved, the Directors shall have discretion to
determine the terms of the Potential Equity Raise, including the number of New
Shares to be issued (subject to the limits of the authorities) and the price
at which the New Shares will be issued, as well as the identity of who the New
Shares will be issued to. Further details of the Potential Equity Raise (if it
proceeds) will be announced in due course.

 

The Circular has been posted to the Shareholders today and is available to
view on, and download from, the Company's website at
www.allergytherapeutics.com.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

 

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZMMZZMDGKZZ



            Copyright 2019 Regulatory News Service, all rights reserved